120638-55-3

中文名称 (2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠

英文名称 Bromfenac Sodium Sesquihydrate

CAS 120638-55-3

分子式 C15H11BrNNaO3

分子量 356.15

MOL 文件 120638-55-3.mol

更新日期 2024/04/21 08:59:31

120638-55-3 结构式

基本信息物理化学性质安全数据常见问题列表

基本信息

中文别名

溴芬酸钠
溴酚酸钠
溴芬那酸钠
溴芬酸钠水合物
溴芬那酸钠水合物
溴芬酸钠120638-55-3
(2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠
(2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠水合物
(2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠倍半水合物

英文别名

Duract
Unii-8ecv571Y37
Bromfenac sodiu
Bromfenac ophthalmic
acetate hydrate(2:2:3)
Bromfenac sodium hydrate
BroMfenac sodiuM 1.5H2O
Sodium bromfenate hydrate
Bromfenac ophthalmic solution
Bromfenac Sodium Sesquihydrate

物理化学性质

熔点268-270°C (dec.)

储存条件Refrigerator

安全数据

警示词危险

危险性描述H372-H300

防范说明P260-P264-P270-P314-P501-P264-P270-P301+P310-P321-P330-P405-P501

常见问题列表

生物活性

Bromfenac sodium hydrate (Bromfenac monosodium salt sesquihydrate) 是一种有效的和具有口服活性的 COX 抑制剂，抑制 COX-1 和 COX-2 的 IC50 值分别为 5.56 和 7.45 nM。Bromfenac sodium hydrate 是一种溴化非甾体类抗炎/镇痛药 (NSAID)，通常用于白内障手术后的术后炎症和疼痛以及假晶状体囊状黄斑水肿 (CME) 的研究。

靶点

COX-1

5.56 nM (IC ₅₀ )

COX-2

7.45 nM (IC ₅₀ )

体外研究

Bromfenac (90 μg/mL; 48 h) inhibits TGF-b1-induced extracellular matrix (ECM) synthesis and myoﬁbroblast activation in HConFs and HPFs.
Bromfenac (30-90 μg/mL; 48 h) decreases the protein and mRNA expression levels of FN, COL3, a-SMA, and survivin in a dose-dependent manner in HConFs and HPFs.
Bromfenac (30-90 μg/mL; 48 h) declines the phosphorylated protein levels of AKT, ERK1/2, and GSK-3b-S9 with dosage in HPFs and HConFs.

体内研究

Bromfenac (0.0032-3.16%; 100 or 200 μL; rubbed onto the backs) produces significant anti-inflammatory activity at concentrations as low as 0.1% (4 h pretreatment time) or 0.32% (18h pretreatment time) in rats.
Bromfenac (0.032-3.16%; 100 μL; rubbed onto the paws) produces dose-related anti-inflammatory activity in rats.
Bromfenac (0.032-1.0%; 50 μL) is 26 times more potent than indomethacin in blocking the erythema when applied directly onto the skin area exposed to UV light in guinea pigs.
Bromfenac (0.0032-0.1%; 50μL; rubbed onto the uninjected paw for 4 h per day and 5 days per week) produces a dose and time dependent reduction in the paw volume of both hind limbs in rats.
Bromfenac (0.32%; 50μL; rubbed onto the abdomen) produces significant blockade of abdominal constriction to ACh challenge in mice.

Animal Model:	Male Sprague-Dawley rats (150-250 g) are injected carrageenan
Dosage:	0.0032, 0.01, 0.032, 0.1, 0.32, 1.0, 3.16% (100 or 200 μL)
Administration:	Rubbed onto the backs before 1-72 h of injected carrageenan
Result:	Produced significant anti-inflammatory activity when applied 1, 2, and 4 h prior to carrageenan challenge at 0.32%. Applied 1 or 4 h prior to carrageenan challenge was active, but not when applied 24 h (or longer) prior to challenge at 0.2%.